MAP gets US complete response letter for migraine drug
This article was originally published in Scrip
Executive Summary
MAP Pharmaceuticals said it will continue to pursue approval of Levadex (dihydroergotamine) inhalation aerosol for the acute treatment of migraine in adults and plans to request a meeting with the US FDA following a complete response letter (CRL) from the agency.